Evidence map›Paper›PMID 38526612›Full record

Trial reportActa neuropathologica2024

A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.

Carolina M Casselini, Henri K Parson, Katie E Frizzi, Alex Marquez, Darrell R Smith, Lucie Guernsey, Rakesh Nemmani, Alireza Tayarani, Corinne G Jolivalt, Jessica Weaver and 3 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Discovery of VU6077564: A Selective MACS chemical neuroscience · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Carolina M CasseliniDepartment of Internal Medicine, Strelitz Diabetes Center, Endocrine and Metabolic Disorders, Eastern Virginia Medical School, Norfolk, VA, USA.
Henri K ParsonDepartment of Internal Medicine, Strelitz Diabetes Center, Endocrine and Metabolic Disorders, Eastern Virginia Medical School, Norfolk, VA, USA.
Katie E FrizziDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Alex MarquezDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Darrell R SmithDivision of Neurodegenerative Disorders, St Boniface Hospital Albrechtsen Research Centre, R4046 - 351 Taché Ave, Winnipeg, MB, R2H 2A6, Canada.
Lucie GuernseyDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Rakesh NemmaniDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Alireza TayaraniDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Corinne G JolivaltDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-4391-1341
Jessica WeaverDepartment of Internal Medicine, Strelitz Diabetes Center, Endocrine and Metabolic Disorders, Eastern Virginia Medical School, Norfolk, VA, USA.
Paul FernyhoughDivision of Neurodegenerative Disorders, St Boniface Hospital Albrechtsen Research Centre, R4046 - 351 Taché Ave, Winnipeg, MB, R2H 2A6, Canada.
Aaron I VinikDepartment of Internal Medicine, Strelitz Diabetes Center, Endocrine and Metabolic Disorders, Eastern Virginia Medical School, Norfolk, VA, USA.
Nigel A CalcuttDepartment of Pathology, University of California San Diego, La Jolla, CA, USA. ncalcutt@ucsd.edu.
University of California San Diego · USEastern Virginia Medical School · USSt. Boniface Hospital · CA

Funding

national Institute of health DK102032NIDDK NIH HHS R21 DK102032
6 · The paper itself

Abstract

Preclinical studies indicate that diverse muscarinic receptor antagonists, acting via the M

Indexed as

Diabetic NeuropathiesMuscarinic AntagonistsAnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansMandelic AcidsMiceQuality of LifeRatsReceptors, MuscarinicMandelic AcidsMuscarinic AntagonistsoxybutyninReceptors, MuscarinicDiabetic neuropathyEpidermal nerve fibresMuscarinic antagonistNeuropathic painOxybutyninRandomized clinical trial

Identifiers

PMID38526612
OpenAlexW4393149656

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.